Anzeige
Mehr »
Freitag, 26.09.2025 - Börsentäglich über 12.000 News
Hot Stock: KI-Boom treibt Kupfer in neue Dimensionen - jetzt profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H5GS | ISIN: SE0010323311 | Ticker-Symbol: B9A
Tradegate
26.09.25 | 09:05
24,980 Euro
-5,95 % -1,580
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOARCTIC AB Chart 1 Jahr
5-Tage-Chart
BIOARCTIC AB 5-Tage-Chart
RealtimeGeldBriefZeit
25,28025,36009:08
25,28025,38009:08

Aktuelle News zur BIOARCTIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBioArctic Says Australia Approves Leqembi For Early Alzheimer's Disease228TOKYO (dpa-AFX) - BioArctic AB (BRCTF) announced Wednesday that Australia's Therapeutic Goods Administration (TGA) has approved Leqembi for the treatment of adults with early Alzheimer's disease.BioArctic...
► Artikel lesen
MiBioArctic: Leqembi approved for the treatment of early Alzheimer's disease in Australia177STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab...
► Artikel lesen
09.09.BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025548STOCKHOLM, Sept. 9, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) CEO, Gunilla Osswald, has been awarded the title...
► Artikel lesen
03.09.BioArctic's founders intend to divest minor part of their shareholding375STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors...
► Artikel lesen
03.09.BioArctic: Rolling sBLA initiated to the U.S. FDA for Leqembi Iqlik (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status400STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics...
► Artikel lesen
01.09.BioArctic: FDA gibt grünes Licht für Alzheimer-Medikament in neuer Darreichungsform489Die Aktien des schwedischen Biotech-Unternehmens BioArctic legten am Montag um mehr als zwei Prozent zu. Hintergrund ist die Zulassung einer neuen Version des Alzheimer-Mittels Leqembi durch die US-Arzneimittelbehörde...
► Artikel lesen
01.09.BioArctic rises as FDA clears Leqembi injection for maintenance use11
BIOARCTIC Aktie jetzt für 0€ handeln
30.08.BioArctic: US FDA approves Leqembi IQKLIK (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease685STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics...
► Artikel lesen
28.08.Novartis pokert groß - Alzheimer-Deal mit BioArctic lässt Aktie steigen24
28.08.BioArctic: Interim Report for the period April - June 2025334Increasing Leqembi® royalties and new partnership with Novartis STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- Events during the second quarter 2025 The European Commission granted...
► Artikel lesen
27.08.Novartis Licenses BioArctic's BrainTransporter Technology4
26.08.Novartis and BioArctic sign collaboration and license deal15
26.08.Novartis pens BioArctic pact worth $30M upfront to find new drug in neurodegeneration field8
26.08.BioArctic soars 13% after $30 mln Novartis deal, third tie-up for BrainTransporter19
26.08.BrainTransporter-Technologie: Novartis forscht mit BioArctic11
26.08.BioArctic, Novartis Partner To Develop New Treatment Using BrainTransporter Technology482BASEL (dpa-AFX) - BioArctic AB (BIOA_B.ST) Tuesday said it has entered into an option, collaboration and license agreement with Novartis Pharma AG (NVS) to develop a new treatment using BioArctic's...
► Artikel lesen
26.08.BioArctic schließt 30-Millionen-Dollar-Deal mit Novartis für Technologie zum Wirkstofftransport ins Gehirn10
26.08.BioArctic signs $30 million deal with Novartis for brain drug delivery tech4
26.08.BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter for an upfront payment of USD 30 million plus additional potential milestones and royalties335STOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with...
► Artikel lesen
25.08.BioArctic, Eisai Unveil Leqembi Therapy For Alzheimer's Treatment In Austria, Germany5
Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1